Recently, the Nanjing Major Project Fund has successfully completed a 100 million yuan investment in Nanjing Ningdan New Drug Technology Co., Ltd. (hereinafter referred to as "Ningdan New Medicine"). This investment will accelerate Ningdan New Medicine's progress in the field of innovative drug research and development.

Ningdan New Medicine is an innovative company focusing on the R&D and industrialization of new drugs in the field of central nervous system (CNS) diseases. Founded on December 28, 2020, the company currently has a research institute composed of nearly 100 researchers with rich experience in new drug R&D, as well as a complete GMP production base. Based on its existing sublingual preparation R&D platform, multi-target drug R&D platform and compound drug R&D platform, the company is advancing the clinical research or clinical application submission of multiple CNS new drug projects at various stages in an orderly manner. Among them, Xianbixin® Sublingual Tablets (generic name: Edaravone Dexborneol Sublingual Tablets) — an innovative drug for stroke co-developed by Ningdan New Medicine and Simcere Pharmaceutical — was approved for marketing by the National Medical Products Administration (NMPA) on December 1, 2024. It is used to improve neurological symptoms, activities of daily living and functional impairments caused by acute ischemic stroke. The product has also received the "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (FDA), making it the first innovative drug in this therapeutic field to obtain such a designation.

Yan Peng'an, General Manager of the Investment Department III of the Venture Capital Group, stated: "The Venture Capital Group highly values Ningdan New Medicine's strength and potential in the R&D field of innovative drugs for central nervous system (CNS) diseases. Ningdan New Medicine has a professional and innovative R&D team that possesses unique insights and profound technical accumulation in the R&D of drugs for neurological diseases. The successful market launch of its core product, Xianbixin® Sublingual Tablets, fully demonstrates the company's R&D capabilities and product quality. We believe this investment will help Ningdan New Medicine further accelerate the development and market launch process of its core product pipeline, provide high-quality treatment solutions for more patients with CNS diseases worldwide, and we also look forward to working hand in hand with Ningdan New Medicine to create a bright future."

Nanjing Venture Capital Group is concentrating its efforts on building Nanjing's "4+N" industrial fund cluster, and has always taken fostering and supporting the development of industrial projects as its responsibility. In the future, the Venture Capital Group will continue to streamline its pace, improve efficiency, accelerate the implementation of a number of major projects with strong innovation capabilities and great development potential, foster and expand technology-based enterprises in a phased manner, and contribute to Nanjing's comprehensive efforts in advancing the construction of a city with strong industries.

Source: Yan Peng'an from Investment Department III

Review: Xue Yao

Release: You Yi